Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach

Fundamental and Clinical Pharmacology

Volumn 13, Issue 5, 1999, Pages 595-604

  Odoul, Franck ^a   Le Guellec, Chantai ^a   Lamagnère, Jean Pierre ^a   Breilh, Dominique ^b   Saux, Marie Claude ^b   Paintaud, Gilles ^a   Autret Leca, Elisabeth ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Anticancer drugs; Drug monitoring; Methotrexate; Pharmacokinetics; Population approach

Indexed keywords

METHOTREXATE;

ACCURACY; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BAYES THEOREM; CHILD; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG MONITORING; FEMALE; HUMAN; MALE; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SAMPLING;

EID: 0033304167     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1999.tb00366.x     Document Type: Article

References (34)

1. Methotrexate
2. Drug dosage and remission duration in childhood lymphocytic leukaemia
3. High-dose methotrexate in acute lymphocytic leukaemia
4. Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukaemia
5. Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia
6. Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukaemia in children
7. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukaemia. Identification of a relation between concentration and effect
8. Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients
9. Use of serum pharmacokinetics to predict and prevent methotrexate toxicity
10. Significance of the 48 hour serum level in high-dose methotrexate regimens
11. Therapeutic drug monitoring in cancer management
12. Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukaemia
13. Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance
14. Patient characteristics associated with high-risk methotrexate concentrations and toxicity
15. Population pharmacokinetics. Theory and clinical application
16. Forecasting individual pharmacokinetics
17. Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, Bayesian feedback and individualised target goals
18. A formula to estimate the approximate surface area if height and weight be known
19. A simple estimate of glomerular filtration rate in children derived from body length and serum creatinine
20. Prediction of creatinine clearance from serum creatinine
21. Population kinetics and conditional assessment of the optimal dosage regimen using the P-Pharm software package
22. A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modelling program P-Pharm
23. Some suggestions for measuring predictive performance
24. Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate in man
25. A pharmacokinetic model for high-dose methotrexate infusions in man
26. Comparison of 2- and 3-compartment models for the Bayesian estimation of methotrexate pharmacokinetics
27. Pharmacokinetics of continuous infusion of methotrexate and teniposide in paediatric cancer patients
28. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukaemia
29. 2 in children with acute lymphoblastic leukaemia
30. Dose dependent methotrexate elimination following bolus intravenous injection
31. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukaemia
32. Dosage adjustment of high-dose methotrexate using Bayesian estimation: A comparative study of two different concentrations at the end of 8 h infusion
33. Bayesian estimation and prediction of clearance in high-dose methotrexate infusions